Printer Friendly

Genta Incorporated Announces Third Quarter 2006 Financial Results and Corporate Highlights.

- FDA Extends Review Period for Genasense(R) NDA for CLL

- FDA Completes Special Protocol Assessment for CLL Trial

- AML Phase 3 Trial Completes Patient Enrollment

- Melanoma Phase 3 Trial Report Published in Journal of Clinical Oncology

- EORTC Confirms Survival Impact of LDH Biomarker in Melanoma

- Response to EMEA Review Questions Completed in Melanoma

- Orphan Drug Designation in Advanced Melanoma Granted in Australia

- New c-myb Antisense Drug Enters Phase 1 Clinical Trial

BERKELEY HEIGHTS, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Genta Incorporated today announced financial results and progress for the quarter ended September 30, 2006. The Company has recently achieved significant milestones, including:
 GENASENSE CLINICAL AND REGULATORY ACTIVITY

 Chronic Lymphocytic Leukemia



On October 29, 2006, Genta was notified that the Food and Drug Administration (FDA) had extended the regulatory review period of the Company's pending New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection from October 29, 2006 to January 29, 2007. The NDA proposes the use of Genasense plus chemotherapy for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). On September 6, 2006, the NDA was presented before FDA's Oncologic Drugs Advisory Committee (ODAC) and did not receive a majority vote to recommend approval. In October, following discussion with FDA, the Company submitted new data analyses that comprised a major amendment to the pending NDA.

On October 6, 2006, Genta announced that its proposed trial of Genasense plus fludarabine and rituximab (Rituxan(R); Genentech, Inc.) in previously untreated patients with CLL had completed Special Protocol Assessment (SPA) by FDA. The Company has indicated that a decision regarding initiation of this trial will not be made until FDA has completed its review of the pending NDA. While the NDA remains under active review, Genta will provide Genasense at no cost to CLL patients in response to single-patient, "compassionate use" requests.

Melanoma

Genta has filed a Marketing Authorization Application (MAA) that is currently under review by the European Medicines Agency (EMEA) for the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. As part of that review, the Company received a consolidated list of questions from the EMEA on June 1, 2006, and -- after meeting with representatives from both rapporteur countries -- Genta has now filed its complete response. While timelines cannot be stated with certainty, the Company currently expects that an opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the status of its application will be available during the first quarter of 2007.

Genasense was designated an Orphan Drug for treatment of patients with Stage IV melanoma by the Therapeutic Goods Administration (TGA), the regulatory authority in Australia. Orphan Drug designation may facilitate the development of drugs that address significant unmet medical needs, and it provides 7 years of market exclusivity after approval, grants and tax credits for research and development, and reduced filing fees for marketing applications. Genta has retained an agent in Australia to act on its behalf for regulatory affairs.

Preliminary results of a collaborative study between Genta and the Melanoma Group of the European Organization for the Research and Treatment of Cancer (EORTC) were presented at a scientific meeting in September 2006. This analysis confirmed the strong relationship between multiple outcomes (including overall survival, progression-free survival, overall response, and durable response) and a blood biomarker, lactate dehydrogenase (LDH). This biomarker was prospectively specified by stratification prior to randomization in Genta's Phase 3 trial of Genasense in advanced melanoma. Results of the Phase 3 trial were published in the October 10, 2006 issue of The Journal of Clinical Oncology, accompanied by an editorial that discusses the trial's results in the context of current options for melanoma treatment. The article can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1

Acute Myeloid Leukemia

In October 2006, the Company announced that target patient accrual had been completed into a randomized Phase 3 trial of Genasense plus chemotherapy in previously untreated patients with acute myeloid leukemia (AML). The trial was conducted by the Cancer and Leukemia Group B (CALGB), the largest U.S. oncology cooperative group, and was sponsored by the National Cancer Institute (NCI). In this trial, more than 500 previously untreated patients were randomly assigned to receive standard induction and consolidation chemotherapy with or without Genasense. Data from this trial are expected to be available during 2007. The Company believes a positive result from this trial may be sufficiently robust to support worldwide regulatory applications for Genasense in AML.

NEW PIPELINE DRUG BEGINS CLINICAL TRIALS

In October, Genta announced initiation of a Phase 1 trial of a new anticancer drug from the company's DNA/RNA Medicines program. The new compound, known as G4460, uses antisense technology to target a key regulatory proto-oncogene known as c-myb. Using an accelerated dosing schedule, this study will evaluate dosing regimens, safety, biologic activity, and down-regulation of c-myb in patients with advanced hematologic cancers. The clinical trial will be conducted using the General Clinical Research Center at the University of Pennsylvania, Philadelphia, PA. Genta has applied for and received Orphan Drug designation from FDA for the use of G4460 as treatment for patients with chronic myelocytic leukemia (CML).

FINANCIAL INFORMATION

For the third quarter of 2006, the Company reported a net loss of $14.9 million, or $0.11 per share, compared to a net loss of $7.9 million, or $0.07 per share, for the third quarter of 2005. In the third quarter of 2006, total operating expenses were $15.5 million, compared to $8.1 million in the prior-year period. The increase was primarily due to higher research and manufacturing expenses, and the planned expansion of our sales and marketing activities in anticipation of a possible commercial approval and launch of Genasense, as well as $0.9 million in stock option-related expense recognized as a result of the adoption of Statement of Financial Accounting Standards No. 123R, "Share-Based Payment," on January 1, 2006.

As of September 30, 2006, Genta had no long-term debt, $0.1 million in short-term debt, and cash, cash equivalents, and marketable securities of $40.1 million, compared to $21.3 million as of December 31, 2005. On September 25, 2006, the Company sold 20 million shares of its common stock at a price of $0.79 per share for gross proceeds of $15.8 million, before fees and expenses. Net cash used in operating activities through September 30, 2006 was $33.5 million, which represents an average monthly outflow of $3.7 million.

Conference Call and Webcast

Genta management will host a conference call and live audio webcast to discuss financial results and general corporate activities on November 7, 2006 at 8:00 am EDT.
 US/Canada call: 877-634-8606; conference code Genta Incorporated
 International call: 706-679-3140; conference code Genta Incorporated
 Webcast: http://www.genta.com/genta/InvestorRelation/events.html




The webcast will be archived for 30 days. Audio replay will be available approximately two hours after completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S./Canada) and (706) 645-9291 (International); conference ID number is 3540311.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the company's lead compound from its oligonucleotide program. The Company has submitted a New Drug Application (NDA) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com/.

Safe Harbor

This press release and the conference call to follow may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:
 * the company's ability to obtain necessary regulatory approval for
 Genasense(R) from the U.S. Food and Drug Administration ("FDA") or
 European Medicines Agency ("EMEA");
 * the safety and efficacy of the company's products or product candidates;
 * the company's assessment of its clinical trials;
 * the commencement and completion of clinical trials;
 * the company's ability to develop, manufacture, license and sell its
 products or product candidates;
 * the company's ability to enter into and successfully execute license and
 collaborative agreements, if any;
 * the adequacy of the company's capital resources and cash flow
 projections, and the company's ability to obtain sufficient financing to
 maintain the company's planned operations;
 * the adequacy of the company's patents and proprietary rights;
 * the impact of litigation that has been brought against the company and
 its officers and directors;
 * the Company's ability to regain compliance with the NASDAQ's listing
 qualifications; and
 * the other risks described under Certain Risks and Uncertainties Related
 to the company's Business, as contained in the company's Annual Report
 on Form 10-K and Quarterly Report on Form 10-Q.




The company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the company's Annual Report on Form 10-K for 2005 and its most recent quarterly report on Form 10-Q.
 Genta Incorporated
 Selected Condensed Consolidated Statements of Operation
 (In thousands, except per share data)
 (Unaudited)


 Three Months Ended Nine Months Ended
 September 30 September 30
 2006 2005 2006 2005
 Revenues:
 License fees / Development
 Funding $- $- $- $26,229
 Product sales - net 145 86 591 259
 Total revenues 145 86 591 26,488

 Cost of goods sold 41 22 79 35

 Operating expenses:
 Research and development 8,514 4,619 21,900 14,040
 Selling, general and
 administrative 6,939 3,495 19,112 12,116
 Loss on disposition of property
 and equipment - 1 - 4
 Total operating expenses - gross 15,453 8,115 41,012 26,160
 sanofi-aventis reimbursement - - - (6,090)
 Total operating expenses - net 15,453 8,115 41,012 20,070

 Gain on forgiveness of debt - - - 1,297
 Other income, net 409 147 1,023 361
 Net (loss) / income $(14,940) $(7,904) $(39,477) $8,041

 Net (loss) / income per basic and
 diluted share $(0.11) $(0.07) $(0.31) $0.08

 Shares used in computing basic net
 (loss) / income per share 135,587 105,629 129,116 98,820

 Shares used in computing diluted net
 (loss) / income per share 135,587 105,629 129,116 99,015



 Selected Condensed Consolidated Balance Sheet Data
 (Unaudited)

 September 30 December 31
 2006 2005
 Cash, cash equivalents and
 marketable securities $40,117 $21,282
 Working capital 28,005 11,703
 Total assets 44,560 27,386
 Total stockholders' equity 31,259 15,697



CONTACT: Tara Spiess, or Andrea Romstad, both of TS Communications Group, LLC, +1-908-286-3980, for info@genta.com

Web site: http://www.genta.com/ http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1 http://www.genta.com/genta/InvestorRelation/events.html
COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 2006
Words:1924
Previous Article:Cambridge Antibody Technology to Expand Operations In Cambridge, UK.
Next Article:Options Group Releases 2006 Global Financial Market Overview and Compensation Report.
Topics:


Related Articles
Genta to Address Year End Financial 2002 Results and Progress In Conference Call and Webcast.
Genta to Release First Quarter 2005 Financial Results on May 9, 2005.
Genta Incorporated Hosts Conference Call to Discuss First Quarter Highlights and Financial Results.
Genta Incorporated Announces First Quarter 2006 Financial Results and Corporate Highlights.
Genta Incorporated to Host Conference Call to Discuss Second Quarter Highlights and Financial Results.
Genta Incorporated Announces Second Quarter 2006 Financial Results and Corporate Highlights.
Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results.
Genta Incorporated to Host Conference Call to Discuss Fourth Quarter Highlights and 2006 Financial Results.
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights.
Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters